Precision Therapeutics Inc. (NASDAQ: AIPT) Secures Lab Status in NIIMBL Drug Safety Grant, Furthers Aim of Improving Medical Care
The global precision medicine market is expected to reach revenues of over $216.75 billion by 2028, propelled by a growing interest in personalized approaches to disease treatments and the application of new technologies Precision Therapeutics and its three wholly owned subdivisions are advancing the company’s goals of applying artificial intelligence to precision medicine and drug research to improve patient care The company’s Helomics subdivision analyzes disease data, particularly in targeting cancer therapies, and develops applicable technologies; the TumorGenesis division develops tumor-fighting tactics, and the Skyline Medical division markets a device that facilitates biological fluid collection in the medical arena Helomics…
